Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing

Current treatment strategies in chronic myeloid leukemia

(2012) François Guilhot et al.   CURRENT OPINION IN HEMATOLOGY

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

Cancer biomarkers: selecting the right drug for the right patient

(2012) Gary J. Kelloff et al.   NATURE REVIEWS DRUG DISCOVERY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation

(2012) Frank S Ong et al.   PHARMACOGENOMICS

BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers

(2012) Yoshiko Shimizu et al.   PLoS One

An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer

(2011) Agustí Barnadas et al.   ADVANCES IN THERAPY

The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms

(2011) L. Arcaini et al.   BLOOD

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation

(2011) E. Tiacci et al.   BLOOD

High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies

(2011) Elaine M. Boyd et al.   BRITISH JOURNAL OF HAEMATOLOGY

Laboratory methods forKRASmutation analysis

(2011) Steven M Anderson   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

(2011) Manfred Schmitt et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Integrating biomarkers in clinical trials

(2011) Marc Buyse et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphatidylinositide-3-Kinase Inhibitors: Addressing Questions of Isoform Selectivity and Pharmacodynamic/Predictive Biomarkers in Early Clinical Trials

(2011) Paul A. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

The cell cycle and cancer

(2011) Gareth H Williams et al.   JOURNAL OF PATHOLOGY

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID?

(2011) Victoria C. Hodgkinson et al.   Journal of Proteomics

Gene expression profiling in breast cancer: classification, prognostication, and prediction

(2011) Jorge S Reis-Filho et al.   LANCET

Predictive biomarkers: a paradigm shift towards personalized cancer medicine

(2011) Nicholas B. La Thangue et al.   Nature Reviews Clinical Oncology

Integrating predictive biomarkers and classifiers into oncology clinical development programmes

(2011) Robert A. Beckman et al.   NATURE REVIEWS DRUG DISCOVERY

BRAFMutations in Hairy-Cell Leukemia

(2011) Enrico Tiacci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microgranular variant of acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR

(2011) Catherine Lewis et al.   Cancer Genetics

HISTORY OF ACUTE PROMYELOCYTIC LEUKEMIA: A TALE OF ENDLESS REVOLUTION

(2011) Francesco Lo-Coco et al.   Mediterranean Journal of Hematology and Infectious Diseases

Targeting BRAF for patients with melanoma

(2010) H-T Arkenau et al.   BRITISH JOURNAL OF CANCER

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

(2010) M. Mino-Kenudson et al.   CLINICAL CANCER RESEARCH

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Emerging companion diagnostics for cancer drugs

(2010) Jocelyn August   NATURE REVIEWS DRUG DISCOVERY

Personalized medicine in oncology: the future is now

(2010) Richard L. Schilsky   NATURE REVIEWS DRUG DISCOVERY

Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy

(2010) Keiran S.M. Smalley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Technical aspects and clinical applications of measuringBCR-ABL1transcripts number in chronic myeloid leukemia

(2009) Letizia Foroni et al.   AMERICAN JOURNAL OF HEMATOLOGY

EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues

(2009) Maria Paola Martelli et al.   AMERICAN JOURNAL OF PATHOLOGY

Hereditary Breast Cancer: Part II. Management of Hereditary Breast Cancer: Implications of Molecular Genetics and Pathology

(2009) Edibaldo Silva et al.   Breast Journal

Hereditary Breast Cancer: Part I. Diagnosing Hereditary Breast Cancer Syndromes

(2009) Henry T. Lynch et al.   Breast Journal

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

(2008) Grazia Arpino et al.   ENDOCRINE REVIEWS

Hereditary breast cancer: new genetic developments, new therapeutic avenues

(2008) Philippe M. Campeau et al.   HUMAN GENETICS

Variation of Breast Cancer Risk Among BRCA1/2 Carriers

(2008) Colin B. Begg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

(2008) Kentaro Inamura et al.   Journal of Thoracic Oncology

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

(2008) Cesare Gridelli et al.   Journal of Thoracic Oncology

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE